Allergic bronchopulmonary aspergillosis in pediatric patients with cystic fibrosis

Česká verzia

Authors: Z. Hribíková; A. Feketeová
Authors place of work: Klinika detí a dorastu UPJŠ LF a DFN Košice, Slovensko
Published in the journal: Čes-slov Pediat 2019; 74 (7): 411-423.
Category:

Summary

Allergic bronchopulmonary aspergillosis (ABPA) is hypersensitive IgE-associated reaction, which occurs as a response of predisposed host to the colonisation of bronchial tree by fungal pathogen Aspergillus fumigatus with production of specific IgE antibodies against certain aspergillus antigens. It occurs almost exclusively in patients with cystic fibrosis or asthma. The disease manifests with increased frequency of pulmonary exacerbations not responding well to conventional therapy, while these exacerbations are characterised by increased mucus and sputum production as well as recurrect attacks of bronchial obstruction. If ABPA is not diagnosed and treated soon enough, it could cause accelerated progression of pulmonary fibrotisation together with the development of cylindrical central bronchiectasis and also lead to irreversible airway damage. Submitted text contains not only an introduction to the topic of such a complex disease, but also a short report on a small cohort of patients with ABPA and cystic fibrosis who are under care of our pediatric center in Košice.

Keywords:

Cystic fibrosis – Aspergillus fumigatus – allergic bronchopulmonary aspergillosis

Zdroje

1. Zápalka M, Kopřiva F, Raclavský V. Aspergillus fumigatus a plicní postižení u cystické fibrózy – přehled problematiky. Čes-slov Pediat 2015; 70 (6): 342–350.

2. Perisson C, Destruys L, Grenet D, et al. Omalizumab treatment for allergic bronchopulmonary aspergillosis in young patients with cystic fibrosis. Respir Med 2017; 133: 12–15.

3. Janahi IA, Rehman A, Al-Naimi AR. Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Ann Thorac Med 2017; 12 (2): 74–82.

4. Heribanová L. Alergická bronchopulmonální aspergilóza. Prakt Lék 2014; 94 (2): 59–63.

5. Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis – state of the art: Cystic Fibrosis Foundation consensus conference. Clin Infect Dis 2003; 37 (Suppl 3): S225–S264.

6. Shah A, Panjabi C. Allergic aspergillosis of the respiratory tract. Eur Respir Rev 2014; 23 (131): 8–29.

7. Shah A, Panjabi C. Allergic bronchopulmonary aspergillosis: a per-plexing clinical entity. Allergy Asthma Immunol Res 2016; 8 (4): 282–297.

8. Bussamra MHF, Rodrigues JC. Allergic bronchopulmonary aspergillosis in paediatric cystic fibrosis patients. Paediatr Respir Rev 2006; 7 (1): 67–72.

9. Greenberger PA, Bush RK, Demain JG, et al. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol Pract 2014; 2 (6): 703–708.

10. Mastella G, Rainisio M, Harms HK, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Eur Respir J 2000; 16 (3): 464–471.

11. Armstead J, Morris J, Denning DW. Multi-country estimate of different manifestations of aspergillosis in cystic fibrosis. PLoS One 2014; 9 (6): e98502.

12. Zolin A, McKone EF, van Rens J, et al. ECFS Patient Registry Annual Report 2010. https://www.ecfs.eu/sites/default/files/general-content-files/working-groups/ecfs-patient-registry/ECFSPR_Report10_v12014_final_020617.pdf.

13. Zolin A, McKone E, Nährlich L, et al. ECFS Patient Registr Annual Report 2011. https://www.ecfs.eu/sites/default/files/general-content-files/working-groups/ecfs-patient-registry/ECFSPR_Annual_Report_2011_Aug2017.pdf.

14. Zolin A, McKone E, Nährlich L, et al. ECFS Patient Registr Annual Report 2012. https://www.ecfs.eu/sites/default/files/general-content-files/working-groups/ecfs-patient-registry/ECFSPR_Annual_Report_2012_Aug_2017.pdf.

15. Zolin A, McKone EF, van Rens J, et al. ECFS Patient Registry Annual Report 2013. https://www.ecfs.eu/sites/default/files/general-content-files/working-groups/ecfs-patient-registry/ECFSPR_Report2013_02.2016.pdf.

16. Zolin A, McKone EF, van Rens J, et al. ECFS Patient Registry Annual Report 2014. https://www.ecfs.eu/sites/default/files/general-content-files/working-groups/ecfs-patient-registry/ECFSPR_Annual% – 20Report% – 202014_Nov2016.pdf.

17. Zolin A, Naehrlich L, van Rens J et al. ECFS Patient Registr Annual Report 2015. https://www.ecfs.eu/sites/default/files/general-content-images/working-groups/ecfs-patient-registry/ECFSPR_Report2015_Nov2017.pdf.

18. Orenti A, Zolin A, Naehrlich L, et al. ECFS Patient Registry Annual Report 2016. https://www.ecfs.eu/sites/default/files/general-content-images/working-groups/ecfs-patient-registry/ECFSPR_Report2016_06062018.pdf.

19. Orenti A, Zolin A, Naehrlich L, et al. ECFS Patient Registry Annual Report 2017. https://www.ecfs.eu/sites/default/files/general-content-images/working-groups/ecfs-patient-registry/ECFSPR_Report2017_v1.3.pdf.

20. Jubin V, Ranque S, Stremier N, et al. Risk factors for Aspergillus colonisation and allergic bronchopulmonary aspergillosis in children with cystic fibrosis. Pediatr Pulmonol 2010; 45 (8): 764–771.

21. Delhaes L, Frealle E, Pinel C. Serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis: state of the art and further challenges. Med Mycol 2010; 48 (Suppl 1): S77–S87.

22. Knutsen AP, Slavi RG. Allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis. Clin Dev Immunol 2011; 2011: 843763. doi: 10.1155/2011/843763. Epub 2011 Apr 5.

23. Lehmann S, Pfannenstiel C, Friedrichs F, et al. Omalizumab: a new treatment option for allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Ther Adv Respir Dis 2014; 8(5): 141–149.

24. Mahdavinia M, Grammer LC. Management of allergic bronchopulmonary aspergillosis: a review and update. Ther Adv Respir Dis 2012; 6 (3): 173–187.

25. Tracy MC, Okorie CUA, Foley EA, et al. Allergic bronchopulmonary aspergillosis. J Fungi 2016; 2 (2): 17.

26. Thia LP, Balfour Lynn IM. Diagnosing allergic bronchopumonary aspergillosis in children with cystic fibrosis. Paediatr Respir Rev 2009; 10 (1): 37–42.

27. Ohn M, Robinson P, Selvadurai H, et al. Question 11: How should allergic bronchopulmonary aspergillosis be managed in cystic fibrosis. Paediatr Respir Rev 2017; 24: 35–38.

28. Patterson K, Strek ME. Allergic bronchopulmonary aspergillosis. Proc Am Thorac Soc 2010; 7 (3): 237–244.

29. Carsin A, Romain T, Ranque S, et al. Aspergillus fumigatus in cystic fibrosis: an update on immune interactions and molecular diagnostics in allergic bronchopulmonary aspergillosis. Allergy 2017; 72 (11): 1632–1642.

30. Leonardi L, Cinicola BL, Laitano R, et al. Allergic bronchopulmonary aspergillosis: diagnostic and treatment challenges. J Pulm Respir Med 2016; 6 (4): 361.

31. Latzin P, Harti D, Regamey N, et al. Comparison of serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis. Eur Respir J 2008; 31 (1): 36–42.

32. Almeida MB, Bussamra MH, Rodrigues JC. ABPA diagnosis in cystic fibrosis patients: the clinical utility of IgE specific to recombinant Aspergillus fumigatus allergens. J Pediatr 2006; 82 (3): 215–220.

33. Hartl D, Latzin P, Zissel G, et al. Chemokines indicate allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Am J Respir Crit Care Med 2006; 173 (12): 1370–1376.

34. Gernez Y, Dunn CE, Everson C, et al. Blood basophils from cystic fibrosis patients with allergic bronchopulmonary aspergillosis are primed and hyper-responsive to stimulation by aspergillus allergens. J Cyst Fibros 2012; 11 (6): 502–510.

35. Gernez Y, Waters J, Mirković B, et al. Blood basophil activation is a reliable biomarker of allergic bronchopulmonary aspergillosis in cystic fibrosis. Eur Respir J 2016; 47 (1): 177–185.

36. Katelari A, Tzanoudaki M, Noni M, et al. The role of basophil activation test in allergic bronchopulmonary aspergillosis and Aspergillus fumigatus sensitization in cystic fibrosis patients. J Cyst Fibros 2016; 15 (5): 587–596.

37. Agarwal R, Khan A, Garg M, et al. Chest radiographic and computed tomographic manifestations in allergic bronchopulmonary aspergillosis. World J Radiol 2012; 4 (4): 141–150.

38. Agarwal R. High attenuation mucoid impaction in allergic bronchopulmonary aspergillosis. World J Radiol 2010; 2(1): 41–43.

39. Refait J, Macey J, Bui S, et al. CT evaluation of hyperattenuating mucus to diagnose allergic bronchopulmonary aspergillosis in the special condition of cystic fibrosis. J Cyst Fibros 2019; 18 (4): e31–e36.

40. Agarwal R, Chakrabarti A, Shah A, et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy 2013; 43 (8): 850–873.

41. Giavina-Bianchi P, Kalil J. Diagnosis of allergic bronchopulmonary aspergillosis exacerbation. J Allergy Clin Immunol Pract 2017; 5 (6): 1599–1600.

42. Tanou K, Zintzaras E, Kaditis AG. Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: a synthesis of published evidence. Pediatr Pulmonol 2014; 49 (5): 503–507.

43. Ashkenazi M, Sity S, Sarouk I, et al. Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. J Asthma Allergy 2018; 11: 101–107.